Side Effects of fludarabine injection: A Synthesis of Findings from 8 Studies

  1. Home
  2. Side Effects of fludarabine injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of fludarabine injection: A Synthesis of Findings from 8 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of fludarabine injection: A Synthesis of Findings from 8 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Fludarabine is a medication used to treat leukemia, such as chronic lymphocytic leukemia (CLL). Several studies have shown that fludarabine is effective in treating CLL. 7 Fludarabine can be administered alone or in combination with other medications. 3 While fludarabine is an effective treatment for CLL, there are risks of side effects.

Reasons for Side Effects

Fludarabine is a medication that inhibits cell growth. Therefore, fludarabine can affect normal cells as well as leukemia cells, potentially causing side effects.

Common Side Effects

Infection

Fludarabine can cause infection because it suppresses the immune system. 7 It can lead to serious complications like cytomegalovirus (CMV) infection. 7 2

Anemia

Fludarabine can cause anemia as it inhibits the production of red blood cells. 6

Thrombocytopenia

Fludarabine can lead to thrombocytopenia by inhibiting platelet production. 6

Fluid retention

Fludarabine can cause fluid retention as a side effect. 6

Hyperglycemia

Hyperglycemia can occur as a side effect of fludarabine treatment. 6

Bradycardia

Bradycardia is a rare side effect of fludarabine treatment. 6

Herpes simplex

Herpes simplex is a potential side effect of fludarabine treatment. 6

Pneumonia

Fludarabine can lead to pneumonia, especially in patients with a history of recurrent chest infections. 6

Measures for Side Effects

Preventing Infections

Infection prevention is crucial during fludarabine treatment. Practice basic infection control measures like hand washing. Follow your doctor's instructions and take medications such as antibiotics as needed.

Treating Anemia

If anemia becomes severe, treatment like blood transfusion may be necessary.

Treating Thrombocytopenia

If thrombocytopenia becomes severe, treatment like blood transfusion may be necessary.

Comparison Between Studies

Commonalities

Multiple studies have shown that fludarabine is effective in treating CLL. Furthermore, these studies have shown that there is a risk of side effects associated with fludarabine. In particular, infection, anemia, and thrombocytopenia are commonly reported side effects associated with fludarabine administration.

Differences

The administration method of fludarabine, the types of side effects, and their frequency vary among studies. This is likely due to differences in study participants' age and condition, as well as the dosage of fludarabine administered.

Precautions for Applying Research to Daily Life

Fludarabine is an effective drug for treating leukemia such as CLL, but there is a risk of side effects. If you are considering taking fludarabine, consult with your doctor and choose a treatment regimen that is right for you. While taking fludarabine, follow your doctor's instructions and have regular checkups to help with early detection of side effects.

Current Research Limitations

Research on fludarabine side effects is still not sufficient. More research is needed in the future.

Directions for Future Research

Development of new treatments and prevention methods to reduce fludarabine side effects is needed. Further research on fludarabine side effects is necessary.

Conclusion

Fludarabine is an effective medication for treating leukemia such as CLL, but there is a risk of side effects. If you are considering taking fludarabine, consult with your doctor and choose a treatment regimen that is right for you. While taking fludarabine, follow your doctor's instructions and have regular checkups to help with early detection of side effects.

Literature analysis of 8 papers
Positive Content
8
Neutral Content
0
Negative Content
0
Article Type
0
0
0
1
8
1.

Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.

Author: LindemalmS, LiliemarkJ, LarssonB S, AlbertioniF

The distribution of the nucleoside analogs was rapid and uniform. High concentrations were found in highly perfused organs. After 4 h, relatively high activities were found in the skin for CdA and CAFdA, in the thymus for ara-C and the bone marrow for CdA. The nucleoside analog transport to the brain in mice is not primarily dependent upon passive diffusion over a lipophilic barrier, but suggestive of a specific transport mechanism.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].

Author: MengFan-Yi, YangLong-Jiang, XuBing, LiuXiao-Li, ZhengWei-Yang, ZhangYu, HuangFen, SunJing, LiuQi-Fa

Effective leukemia treatment
FLAG regimen side effects

The hematological complete remission (CR) rate of the FLAG regimen for relapsed and refractory acute non-lymphocytic leukemia (ANLL) was 50-64%. This study investigated a modified FLAG regimen, with reduced Ara-C and no G-CSF administration before fludarabine and Ara-C, to examine its effectiveness and potential for fewer side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : Chinese

3.

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.

Author: D'ArenaGiovanni, LaurentiLuca, CapalboSilvana, D'ArcoAlfonso Maria, De FilippiRosaria, MarcacciGianpaolo, Di RenzoNicola, StortiSergio, CalifanoCatello, VigliottiMaria Luigia, TarnaniMichela, FerraraFelicetto, PintoAntonio

CLL-associated AIHA treatment
Cardiac failure
HCV complications
Sepsis

Rituximab, an anti-CD20 monoclonal antibody, was used to treat 14 patients with CLL-associated autoimmune hemolytic anemia. Rituximab demonstrated efficacy and good tolerance, with 22% of patients achieving a complete response and 50% a partial response.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Purine analog toxicity in patients with hairy cell leukemia.

Author: TadmorTamar

Complete remission
HCL treatment
Immune suppression
Secondary malignancy
Stem cell toxicity

The toxicity of cladribine and pentostatin in the treatment of hairy cell leukemia was reviewed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.

Author: MalikAsifa, ShoukierMahran, Garcia-ManeroGuillermo, WierdaWilliam, CortesJorge, BickelSusan, KeatingMichael J, EstrovZeev

CLL treatment

This phase II trial with the hypomethylating agent azacitidine was conducted in patients with recurrent fludarabine-refractory CLL to investigate the potential benefits of demethylation therapy in CLL.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

High dose methyl prednisolone in refractory chronic lymphocytic leukaemia.

Author: ThorntonP D, HamblinM, TreleavenJ G, MatutesE, LakhaniA K, CatovskyD

Treats refractory CLL
Bradycardia
Fluid retention
Herpes simplex
Hyperglycemia
Pneumonia

High-dose methylprednisolone (HDMP) may be beneficial in the treatment of refractory chronic lymphocytic leukemia (CLL) but is of no value in CLL with prolymphocytes.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Author: ByrdJohn C, PetersonBercedis L, RaiKanti R, HurdDavid, HohlRaymond, PerryMichael C, GockermanJon, NattamSreenivasa, LarsonRichard A

Chronic Lymphocytic Leukemia Treatment
Cytomegalovirus Infection
Infection
Infusion-Related Reactions

Alemtuzumab, an anti-CD52 monoclonal antibody, showed feasibility and safety when used as consolidation therapy after fludarabine treatment for chronic lymphocytic leukemia. Close monitoring for CMV infection and other infectious events is necessary.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.